MYD 88 mutations identify a molecular subgroup of
MYD 88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis by Joost S. Vermaat, Sebastiaan F. Somers, Liesbeth C. de Wreede, Willem Kraan, Ruben A. L. de Groen, Anne M. R. Schrader, Emile D. Kerver, Cornelis G. Scheepstra, Henriëtte Berenschot, Wendy Deenik, Jurgen Wegman, Rianne Broers, Jan-Paul D. de Boer, Marcel Nijland, Tom van Wezel, Hendrik Veelken, Marcel Spaargaren, Arjen H. Cleven, Marie José Kersten, and Steven T. Pals haematol Volume 105(2): 424 -434 February 1, 2020 © 2020 by Ferrata Storti Foundation
Patient characteristics at time of diagnosis. Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Hans’ algorithm and molecular analysis at time of diagnosis. Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Oncoprint plot of the molecular analysis of 250 cases with diffuse large B-cell lymphoma (DLBCL). Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Molecular characterization discriminates distinct DLBCL subgroups with prognostic impact. Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Prognostic significance of anatomical location, IPI Score and MYD 88 in DLBCL. OS, PFS, and cumulative incidence of relapse/progression compared to NRM (1 st row: Location, 2 nd row: IPI Score, 3 rd row: MYD 88). Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Prognostic impact of molecular aberrations and IPI risk factors on overall survival: univariable and multivariable analysis. Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Prognostic impact of molecular aberrations and IPI risk factors on relapse/progression: univariable and multivariable analysis. Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
Mutated MYD 88 improved the prognostic performance of the IPI. Joost S. Vermaat et al. Haematologica 2020; 105: 424 -434 © 2020 by Ferrata Storti Foundation
- Slides: 9